TTrialPathMatch Me to Trials
← Back to trials
RecruitingTransthyretin Amyloid Cardiomyopathy (ATTR CM)

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

Eligible age

18+ yrs

Accepts

All genders

Locations

28 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a treatment with no active medicine), and which one they get is decided by chance. Everyone in the study will continue receiving their usual heart treatments as recommended by their doctor.

Sponsor: Novo Nordisk A/S

You may qualify if…

  • ✓ 1. Male or female.
  • ✓ 2. Age 18 years or above at the time of signing the informed consent.
  • ✓ 3. Have an established diagnosis of ATTR-CM (wild-type ATTR \[ATTRwt\] or variant ATTR \[ATTRv\]), with cardiac amyloid infiltration, increased left ventricular (LV) wall thickness, and HF.
  • ✓ Note: Target ATTRv recruitment is approximately 15 percent of the study population.
  • ✓ a. Cardiac amyloid infiltration demonstrated by: i. Cardiac biopsy positive for TTR amyloid, OR ii. Grade 2 or 3 cardiac uptake at pyrophosphate (PYP)/diphosphono-1,2-propanodicarboxylic acid (DPD)/ hydroxymethylene diphosphonate (HMDP) nuclear medicine imaging with single-photon emission computed tomography (SPECT) or SPECT/CT (preferably) combined with an extracardiac biopsy positive for TTR amyloid, OR iii. Grade 2 or 3 cardiac uptake at PYP/DPD/HMDP nuclear medicine imaging with SPECT or SPECT/CT (preferably) combined with normal serum free light chain ratio, and negative serum and urine protein electrophoresis with immunofixation (SPIE \& UPIE)/or mass spectrometry based methods including mass fixation).
  • ✓ Notes:
  • ✓ Non-invasive diagnostic pathway will be confirmed by a centralised expert review.
  • ✓ Bone tracer nuclear medicine imaging with SPECT or SPECT/CT (preferably) will be conducted using 99m-technetium (Tc)-labelled pyrophosphate (99mTc-PYP), 99mTc-labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD), or 99mTc-labeled hydroxymethylene diphosphonate (99mTc-HMDP).

You may not qualify if…

  • ✕ 1. Known or suspected hypersensitivity to study intervention(s) or related products.
  • ✕ 2. Current or previous participation (dosing with active treatment) in a study for an investigational ATTR depleting drug or ATTR gene editing therapy.
  • ✕ 3. Total bilirubin greater than 3 times the upper limit of normal (ULN) at screening.
  • ✕ 4. Current diagnosis or history of amyloid light chain, other non-ATTR amyloidosis, known leptomeningeal amyloidosis, or multiple myeloma.
  • ✕ 5. HF not primarily caused by ATTR-CM (e.g., due to hypertension, valvular heart disease, or ischemic heart disease in the opinion of the investigator).
  • ✕ 6. Currently hospitalised or hospitalised within 14 days prior to screening.
  • ✕ 7. Currently treated with positive inotropic medication.
  • ✕ 8. Uncorrected, severe, haemodynamically significant, left-sided heart valve disease.

Where it's recruiting

Arizona

Phoenix

California

La Jolla · Los Angeles · Orange · Pasadena …

Connecticut

New Haven

District of Columbia

Washington D.C.

Florida

Gainesville

Georgia

Gainesville

Hawaii

Honolulu

Illinois

Chicago · Glenview

Indiana

Indianapolis

Louisiana

New Orleans

Maryland

Baltimore

Source: ClinicalTrials.gov · NCT07207811 · last updated 2026-10-21